Group 1 - Multiple companies conducted share buybacks on October 21, 2025, with a total of 30 companies listed [1] - The largest buyback was by Cloud Factory (N23027), repurchasing 2.1 million shares for a total of 8.22 million yuan [1][2] - Other notable buybacks include Linklogis Technology (W09959) with 2.38 million shares for 7.45 million yuan and Mengniu Dairy (02319) with 500,000 shares for 7.26 million yuan [2] Group 2 - Cumulative buyback amounts for the year show Cloud Factory (N23027) has repurchased a total of 26.62 million shares, representing 5.786% of its total share capital [2] - Linklogis Technology (W09959) has repurchased 67.82 million shares, accounting for 3.174% of its total share capital [2] - Other companies with significant cumulative buybacks include Stone Four Pharmaceutical (02005) with 39.20 million shares (1.328%) and Kangchen Pharmaceutical (01681) with 6.50 million shares (7.637%) [2][3]

Core Points - 康臣药业 has been actively repurchasing its shares, with a total of 130.60 million shares repurchased over the past six days, amounting to 20.08 million HKD [2] - The stock price of 康臣药业 has shown a slight increase of 0.39% on the day of the latest repurchase, closing at 15.490 HKD, despite a cumulative decline of 3.19% during the repurchase period [2] - Year-to-date, 康臣药业 has conducted 24 repurchase transactions, totaling 650.10 million shares and an aggregate repurchase amount of 78.61 million HKD [2] Repurchase Details - On October 21, 康臣药业 repurchased 26.90 million shares at a price range of 15.440 to 15.600 HKD, with a total expenditure of 4.17 million HKD [2] - The highest repurchase price recorded during the recent transactions was 15.840 HKD on October 15, while the lowest was 10.960 HKD on July 7 [2][3] - The cumulative repurchase amount for the year has reached 78.61 million HKD, indicating a significant commitment to supporting the stock price [2]

智通财经APP讯，康臣药业(01681)发布公告，于2025年10月21日斥资417万港元回购26.9万股。 ...

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Group 1 - The company will spend HKD 4.17 million to repurchase 269,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康臣葯業集團有限公司 呈交日期： 2025年10月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...

Core Viewpoint - Multiple companies in China conducted share buybacks on October 20, 2025, with notable activity from Mengniu Dairy, which had the largest buyback amount of 10.14 million yuan for 700,000 shares [1][2] Summary by Company - **Mengniu Dairy (02319)**: - Buyback of 700,000 shares - Total buyback amount of 10.14 million yuan - Year-to-date cumulative buyback of 1.92 million shares, representing 0.491% of total share capital [2] - **YunGongChang (N23027)**: - Buyback of 1.87 million shares - Total buyback amount of 7.53 million yuan - Year-to-date cumulative buyback of 2.45 million shares, representing 5.33% of total share capital [2] - **Lianyi Rong Technology (09959)**: - Buyback of 2.45 million shares - Total buyback amount of 7.44 million yuan - Year-to-date cumulative buyback of 6.54 million shares, representing 3.06% of total share capital [2] - **Guoshengtang (02273)**: - Buyback of 232,000 shares - Total buyback amount of 6.83 million yuan - Year-to-date cumulative buyback of 467,810 shares, representing 1.97% of total share capital [2] - **Antong Oilfield Services (03337)**: - Buyback of 4.42 million shares - Total buyback amount of 4.94 million yuan - Year-to-date cumulative buyback of 3.37 million shares, representing 1.14% of total share capital [2] - **Weishi Jiajie (00856)**: - Buyback of 500,000 shares - Total buyback amount of 4.53 million yuan - Year-to-date cumulative buyback of 663,800 shares, representing 0.462% of total share capital [2] - **Beisen Holdings (09669)**: - Buyback of 400,600 shares - Total buyback amount of 3.24 million yuan - Year-to-date cumulative buyback of 143,260 shares, representing 0.204% of total share capital [2] - **Zhongxu Future (09890)**: - Buyback of 228,200 shares - Total buyback amount of 3.13 million yuan - Year-to-date cumulative buyback of 598,580 shares, representing 1.12% of total share capital [2] - **Shoujia Technology (00103)**: - Buyback of 2.8 million shares - Total buyback amount of 2.21 million yuan - Year-to-date cumulative buyback of 5.75 million shares, representing 2.45% of total share capital [2] - **Meili Tianyuan Medical Health (02373)**: - Buyback of 70,000 shares - Total buyback amount of 2.21 million yuan - Year-to-date cumulative buyback of 30,050 shares, representing 0.127% of total share capital [2] - **Kangchen Pharmaceutical (01681)**: - Buyback of 100,000 shares - Total buyback amount of 1.54 million yuan - Year-to-date cumulative buyback of 623,200 shares, representing 7.32% of total share capital [2]

Core Insights - The article discusses the challenges in the field of robotics, particularly the gap between simulation and real-world application, and introduces RoboChallenge.ai as a solution to create a standardized evaluation platform for embodied intelligence [2][42][51]. Group 1: Current Challenges in Robotics - Many models perform well in simulations but fail in real-world scenarios, highlighting a significant pain point in robotics research [2][42]. - The need for a unified, open, and reproducible evaluation system for robotics is emphasized, as current benchmarks are primarily based on simulations [50][44]. Group 2: Introduction of RoboChallenge.ai - RoboChallenge.ai is launched as an open, standardized platform for evaluating robotic models in real-world environments, allowing researchers to remotely test their models on physical robots [6][51]. - The platform enables users to control local models through an API, facilitating remote testing without the need to upload models [8][53]. Group 3: Importance of Open Source in Robotics - Open source is identified as a crucial driver for advancements in AI and robotics, enabling collaboration and innovation across global teams [10][19]. - The article argues that open source in robotics may be even more critical than in large language models (LLMs) due to the necessity of hardware accessibility for model application [20][22]. Group 4: Future Directions and Community Involvement - The article anticipates that the next three to five years will see significant evolution in embodied intelligence research, with robots capable of executing longer and more complex tasks [82]. - Community participation is encouraged, with the expectation that diverse contributions will enhance data availability and model robustness [66][68].

康臣药业(01681)公布，2025年10月20日耗资约154.13万港元回购10万股股份。 ...

Group 1 - The company, Kangchen Pharmaceutical (01681.HK), announced a share buyback plan on October 20, 2025, involving an expenditure of HKD 1.54 million to repurchase 100,000 shares [1] - The buyback price range is set between HKD 15.39 and HKD 15.47 per share [1]

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating a strategic move to enhance shareholder value by repurchasing 100,000 shares at a cost of approximately HKD 1.5413 million [1] Company Summary - 康臣药业 plans to repurchase 100,000 shares on October 20, 2025 [1] - The total expenditure for this buyback is around HKD 1.5413 million [1]